Annandale Capital, LLC Medicenna Therapeutics Corp. Call Options Transaction History

Annandale Capital, LLC

  • $714 Million
  • Q3 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding MDNA

# of Institutions
3
Shares Held
863K
Call Options Held
0
Put Options Held
0
View Full List

About Medicenna Therapeutics Corp.

MDNA Quotes by TradingView
  • Ticker MDNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 69,637,504
  • Market Cap $21.6M
  • Description
  • Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as...
More about MDNA
Track This Portfolio

Track Annandale Capital, LLC Portfolio

Follow Annandale Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Annandale Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Annandale Capital, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email